NIKKEI 225
38,617.10 -329.83 (-0.85%) HANG SENG
19,210.56 -10.06 (-0.05%) CRUDE OIL
79.06 -0.20 (-0.25%) GOLD FUTURES
2,419.30 -6.60 (-0.27%) DOW
39,872.99 +66.22 (+0.17%) Bitcoin GBP
54,788.63 -1,151.83 (-2.06%)
LadRx Corporation (0I5R.L)
- Business Wire
LadRx Issues 2024 Update to Shareholders
LOS ANGELES, January 09, 2024--LadRx Corporation (OTCQB: LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today issued the below letter to shareholders providing a corporate update and anticipated milestones for 2024 regarding arimoclomol and LADR-7.
- Business Wire
LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation
LOS ANGELES, June 22, 2023--LadRx Corporation (OTCQB: LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that it has transferred the royalty and milestone rights associated with arimoclomol and aldoxorubicin to XOMA Corporation (NASDAQ: XOMA) ("XOMA"). In exchange for the future rights to royalties and milestones on arimoclomol and aldoxorubicin, the agreement provides to LadRx $5 million in gros
